Antonio Blazquez

Summary

Publications

  1. doi request reprint Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients
    Antonio Blázquez-Pérez
    Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, C Campezo 1 edificio 8, Planta 2 Oeste E, 28022, Madrid, Spain
    Pharmacoeconomics 31:919-31. 2013
  2. ncbi request reprint Regulatory considerations for generic or biosimilar low molecular weight heparins
    Alfredo García-Arieta
    División de Farmacología y Evaluación Clínica, Subdirección General de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, C Campezo 1 edificio 8, Planta 2 Oeste, E 28022 Madrid, Spain
    Curr Drug Discov Technol 9:137-42. 2012

Collaborators

  • Javier Mar
  • Antonio Blázquez-Pérez
  • Alfredo García-Arieta
  • Ramón San Miguel

Detail Information

Publications2

  1. doi request reprint Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients
    Antonio Blázquez-Pérez
    Departamento de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, C Campezo 1 edificio 8, Planta 2 Oeste E, 28022, Madrid, Spain
    Pharmacoeconomics 31:919-31. 2013
    ..A new scenario of therapy for hepatitis C virus (HCV) genotype 1 infection is being established with the approval of two effective HCV protease inhibitors (PIs) in combination with the standard of care (SOC), peginterferon and ribavirin...
  2. ncbi request reprint Regulatory considerations for generic or biosimilar low molecular weight heparins
    Alfredo García-Arieta
    División de Farmacología y Evaluación Clínica, Subdirección General de Medicamentos de Uso Humano, Agencia Española de Medicamentos y Productos Sanitarios, C Campezo 1 edificio 8, Planta 2 Oeste, E 28022 Madrid, Spain
    Curr Drug Discov Technol 9:137-42. 2012
    ..In contrast, the EMA legislation only deals with the approvability or prescribability of the medicines and it is a national / regional decision of the member States to consider these biosimilar products as interchangeable or not...